Relief Therapeutics Holding SA (SWX:RLF)
Switzerland
· Delayed Price · Currency is CHF 2.370
-0.025 (-1.04%)
Apr 24, 2025, 3:17 PM CET
SWX:RLF Revenue
In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M CHF with 39.52% growth. Relief Therapeutics Holding had revenue of 3.01M in the half year ending December 31, 2023, a decrease of -9.36%.
Revenue
8.42M
Revenue Growth
+39.52%
P/S Ratio
3.57
Revenue / Employee
271.52K
Employees
31
Market Cap
30.03M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.40B |
| Novartis AG | 46.87B |
| Lonza Group AG | 6.57B |
| Alcon | 8.98B |
| Galderma Group AG | 4.02B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.71B |
| Sandoz Group AG | 9.41B |
Relief Therapeutics Holding News
- 14 days ago - Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B - Seeking Alpha
- 14 days ago - Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Accesswire
- 7 weeks ago - Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion - Accesswire
- 2 months ago - Relief Therapeutics to get European patent for investigational drug RLF‑TD011 - Seeking Alpha
- 2 months ago - Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 - Accesswire
- 3 months ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 3 months ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 4 months ago - Relief Therapeutics advances merger talks with Renexxion - Seeking Alpha